More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Acquista questo ebook e ricevine 1 in più GRATIS!
Lingua Inglese ● Formato PDF ● Pagine 584 ● ISBN 9781420037937 ● Casa editrice CRC Press ● Pubblicato 2002 ● Scaricabile 3 volte ● Moneta EUR ● ID 5697838 ● Protezione dalla copia Adobe DRM
Richiede un lettore di ebook compatibile con DRM